Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 9 | 2023 | 115 | 2.920 |
Why?
|
| Melanoma | 2 | 2024 | 30 | 1.660 |
Why?
|
| Health Personnel | 6 | 2018 | 22 | 1.480 |
Why?
|
| Adult | 23 | 2024 | 1683 | 1.360 |
Why?
|
| Middle Aged | 20 | 2024 | 1098 | 1.140 |
Why?
|
| Humans | 36 | 2024 | 5476 | 1.110 |
Why?
|
| Female | 28 | 2024 | 2811 | 1.090 |
Why?
|
| Texas | 13 | 2024 | 190 | 1.080 |
Why?
|
| Immunotherapy | 2 | 2024 | 22 | 1.080 |
Why?
|
| Male | 28 | 2024 | 2765 | 1.070 |
Why?
|
| Retrospective Studies | 17 | 2024 | 382 | 1.070 |
Why?
|
| Medication Adherence | 8 | 2024 | 70 | 1.050 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 28 | 1.010 |
Why?
|
| United States | 15 | 2024 | 521 | 0.920 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 53 | 0.920 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 10 | 0.880 |
Why?
|
| Adolescent | 15 | 2024 | 806 | 0.850 |
Why?
|
| Substance-Related Disorders | 2 | 2023 | 52 | 0.840 |
Why?
|
| Osteoarthritis | 1 | 2023 | 6 | 0.810 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 47 | 0.790 |
Why?
|
| Mental Disorders | 1 | 2023 | 52 | 0.790 |
Why?
|
| Condoms | 3 | 2008 | 6 | 0.780 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 74 | 0.750 |
Why?
|
| Young Adult | 12 | 2024 | 850 | 0.730 |
Why?
|
| Government | 1 | 2021 | 2 | 0.710 |
Why?
|
| Public Opinion | 1 | 2021 | 2 | 0.710 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 22 | 0.670 |
Why?
|
| Hypertension | 5 | 2023 | 61 | 0.650 |
Why?
|
| Multiple Sclerosis | 3 | 2024 | 46 | 0.620 |
Why?
|
| Information Services | 1 | 2018 | 2 | 0.590 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 3 | 0.570 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 4 | 0.570 |
Why?
|
| Smoking | 3 | 2015 | 94 | 0.570 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 5 | 0.560 |
Why?
|
| Medicare Part C | 5 | 2024 | 31 | 0.540 |
Why?
|
| Military Personnel | 2 | 2008 | 23 | 0.540 |
Why?
|
| Motivational Interviewing | 3 | 2023 | 11 | 0.540 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 284 | 0.530 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 9 | 0.510 |
Why?
|
| Smoking Cessation | 5 | 2016 | 137 | 0.500 |
Why?
|
| Aged | 12 | 2024 | 859 | 0.480 |
Why?
|
| Risk Factors | 6 | 2024 | 184 | 0.450 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 15 | 0.440 |
Why?
|
| Obstetric Labor Complications | 1 | 2012 | 1 | 0.390 |
Why?
|
| Symphysiotomy | 1 | 2012 | 1 | 0.390 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 277 | 0.360 |
Why?
|
| Obesity | 4 | 2022 | 118 | 0.350 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 33 | 0.340 |
Why?
|
| Logistic Models | 7 | 2017 | 69 | 0.340 |
Why?
|
| Nigeria | 3 | 2021 | 7 | 0.340 |
Why?
|
| Sex Factors | 3 | 2024 | 81 | 0.310 |
Why?
|
| Safe Sex | 2 | 2008 | 3 | 0.300 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 18 | 0.300 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 18 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 37 | 0.290 |
Why?
|
| Cohort Studies | 3 | 2024 | 131 | 0.280 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 22 | 0.270 |
Why?
|
| Contraception Behavior | 1 | 2006 | 3 | 0.260 |
Why?
|
| Intention | 1 | 2006 | 19 | 0.260 |
Why?
|
| Life Style | 1 | 2006 | 13 | 0.260 |
Why?
|
| Pharmaceutical Services | 2 | 2017 | 18 | 0.250 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 30 | 0.250 |
Why?
|
| Bupropion | 2 | 2016 | 8 | 0.250 |
Why?
|
| Varenicline | 2 | 2016 | 8 | 0.250 |
Why?
|
| Factor Xa Inhibitors | 1 | 2024 | 5 | 0.220 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 8 | 0.220 |
Why?
|
| Rivaroxaban | 1 | 2024 | 6 | 0.220 |
Why?
|
| Recurrence | 1 | 2024 | 26 | 0.220 |
Why?
|
| Pyridones | 1 | 2024 | 8 | 0.220 |
Why?
|
| Markov Chains | 1 | 2024 | 18 | 0.220 |
Why?
|
| Multimorbidity | 1 | 2024 | 4 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 20 | 0.220 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 17 | 0.220 |
Why?
|
| Anticoagulants | 1 | 2024 | 15 | 0.220 |
Why?
|
| Pyrazoles | 1 | 2024 | 19 | 0.220 |
Why?
|
| Registries | 1 | 2024 | 24 | 0.220 |
Why?
|
| Demography | 2 | 2018 | 17 | 0.210 |
Why?
|
| Patient Acuity | 1 | 2023 | 4 | 0.210 |
Why?
|
| Stroke | 1 | 2024 | 53 | 0.210 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 8 | 0.210 |
Why?
|
| Treatment Outcome | 1 | 2024 | 212 | 0.210 |
Why?
|
| Outpatients | 1 | 2023 | 11 | 0.200 |
Why?
|
| Prescriptions | 1 | 2023 | 19 | 0.200 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 3 | 0.190 |
Why?
|
| Education, Pharmacy | 1 | 2024 | 73 | 0.190 |
Why?
|
| Insulin Resistance | 1 | 2022 | 9 | 0.190 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 8 | 0.190 |
Why?
|
| Diabetes Complications | 1 | 2022 | 5 | 0.190 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 16 | 0.180 |
Why?
|
| Medicaid | 2 | 2019 | 29 | 0.180 |
Why?
|
| Interviews as Topic | 1 | 2021 | 24 | 0.170 |
Why?
|
| Medicare | 2 | 2024 | 79 | 0.170 |
Why?
|
| Students, Pharmacy | 2 | 2024 | 73 | 0.170 |
Why?
|
| Immunologic Factors | 3 | 2024 | 18 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2023 | 16 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2023 | 17 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 320 | 0.150 |
Why?
|
| Mental Health Services | 1 | 2018 | 13 | 0.140 |
Why?
|
| HIV | 1 | 2018 | 4 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 20 | 0.140 |
Why?
|
| Counseling | 2 | 2014 | 15 | 0.140 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 43 | 0.140 |
Why?
|
| Prevalence | 2 | 2008 | 72 | 0.140 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 3 | 0.130 |
Why?
|
| Schizophrenia | 1 | 2016 | 8 | 0.130 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 13 | 0.130 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 3 | 0.120 |
Why?
|
| Weight Gain | 1 | 2016 | 28 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 14 | 0.120 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 49 | 0.120 |
Why?
|
| Psychotropic Drugs | 2 | 2018 | 13 | 0.110 |
Why?
|
| Maternal Mortality | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cephalopelvic Disproportion | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cesarean Section | 1 | 2012 | 3 | 0.100 |
Why?
|
| Child | 3 | 2022 | 657 | 0.100 |
Why?
|
| Pregnancy | 1 | 2012 | 103 | 0.090 |
Why?
|
| Jordan | 1 | 2012 | 5 | 0.090 |
Why?
|
| Financing, Personal | 1 | 2008 | 1 | 0.070 |
Why?
|
| Medicare Part D | 1 | 2008 | 7 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2022 | 100 | 0.070 |
Why?
|
| Educational Status | 1 | 2008 | 30 | 0.070 |
Why?
|
| Linear Models | 2 | 2018 | 60 | 0.070 |
Why?
|
| Telephone | 2 | 2017 | 13 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2006 | 49 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2006 | 119 | 0.060 |
Why?
|
| Comorbidity | 2 | 2016 | 49 | 0.060 |
Why?
|
| Public Housing | 1 | 2005 | 1 | 0.060 |
Why?
|
| Videotape Recording | 1 | 2005 | 4 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2005 | 16 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 31 | 0.060 |
Why?
|
| Focus Groups | 1 | 2005 | 16 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 19 | 0.060 |
Why?
|
| Poverty | 1 | 2005 | 22 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2024 | 35 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 31 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2024 | 49 | 0.050 |
Why?
|
| Curriculum | 1 | 2024 | 50 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 3 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 6 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 18 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2022 | 19 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 20 | 0.050 |
Why?
|
| Hospitalization | 1 | 2019 | 38 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 26 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 25 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2019 | 40 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 75 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2019 | 46 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2017 | 132 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 2016 | 15 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 8 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 97 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 34 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 33 | 0.030 |
Why?
|
| Pharmacists | 1 | 2016 | 41 | 0.030 |
Why?
|
| Patient Participation | 1 | 2014 | 6 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 3 | 0.030 |
Why?
|
| Social Stigma | 1 | 2014 | 6 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 6 | 0.030 |
Why?
|
| Urban Health | 1 | 2014 | 5 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 14 | 0.030 |
Why?
|
| Perception | 1 | 2014 | 32 | 0.030 |
Why?
|
| Overweight | 1 | 2014 | 41 | 0.030 |
Why?
|
| Self Report | 1 | 2014 | 72 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 3 | 0.020 |
Why?
|